Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 11,740 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level A Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

NCT02812394
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study Between Colchicine and Cyclosporine

NCT00983931
View directory record Official record
Conditions
Pharmacokinetics, Healthy
Interventions
Colchicine, Cyclosporine
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

NCT00944905
View directory record Official record
Conditions
Renal Cell Carcinoma, Non-hodgkin's Lymphoma
Interventions
MDX-1203
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 24, 2026, 5:10 PM EDT
Enrolling by invitation Not applicable Interventional

Influence of Pre-operative Back Muscle Exercise on Post-operative Outcomes After Spine Surgery

NCT06808022
View directory record Official record
Conditions
Spine Pain, Spine Surgery
Interventions
Preoperative Resistance Exercise
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 24, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional Results available

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

NCT05537402
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

NCT02224053
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine

NCT02131545
View directory record Official record
Conditions
Dementia, Delirium
Interventions
Quetiapine 25 mg gel applied topically, Quetiapine 25 mg tablet by mouth, Quetiapine 25 mg rectal suppository
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 24, 2026, 5:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers of Periodontal Disease Progression

NCT01489839
View directory record Official record
Conditions
Periodontal Disease
Interventions
Periodontal therapy
Other
Lead sponsor
The Forsyth Institute
Other
Eligibility
25 Years and older
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
5
States / cities
Edwardsville, Illinois • Cambridge, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Not applicable Interventional

Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients

NCT03402256
View directory record Official record
Conditions
Alcoholic Liver Disease
Interventions
Text Message
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mindfulness in a College Physiology Course

NCT06423053
View directory record Official record
Conditions
Mindfulness, Stress, Well-being
Interventions
Biology Course with Integrated Mindfulness
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 5:10 PM EDT
Recruiting Phase 1 Interventional

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT06915753
View directory record Official record
Conditions
Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, Locally Advanced Unresectable Hepatocellular Carcinoma
Interventions
TYRA-430
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 24, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional

Evaluation of an Acellular Osteochondral Graft for Cartilage LEsions Pilot Trial

NCT01183637
View directory record Official record
Conditions
Articular Cartilage Injury
Interventions
Kensey Nash Corp. Cartilage Repair Device, Microfracture
Device · Procedure
Lead sponsor
Kensey Nash Corporation
Industry
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Salisbury, Maryland • Kirkwood, Missouri
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Validation of Alcohol Level Identification Using DRIVESC

NCT07282405
View directory record Official record
Conditions
Driving Impaired
Interventions
DRIVESC, Alcohol
Diagnostic Test · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 64 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 5:10 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Apple Hearing Study

NCT04172766
View directory record Official record
Conditions
Hearing Loss, Noise-Induced, Hearing Loss, Tinnitus
Interventions
Not listed
Lead sponsor
Apple Inc.
Industry
Eligibility
18 Years and older
Enrollment
300,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 24, 2026, 5:10 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

NCT04638751
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Interventions
Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy
Drug · Procedure
Lead sponsor
Persephone Biosciences
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
10
States / cities
Orange, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer

NCT00437502
View directory record Official record
Conditions
Epithelial Ovarian, Tubal or Peritoneal Cancer
Interventions
tumor peptide vaccine
Biological
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Not applicable Interventional

Does Physical Therapy Prevent Total Knee Arthroplasty in Patients With End Stage Osteoarthritis

NCT02377102
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Physical Therapy
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Not applicable Interventional Results available

An Intervention to Reduce Second Hand Smoke Exposure Among Pediatric Emergency Patients

NCT02531594
View directory record Official record
Conditions
Smoking Cessation
Interventions
SBIRT, HHC
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease

NCT00871702
View directory record Official record
Conditions
Leukemia, Lymphoma, Non-Hodgkin, Hodgkin Disease, Myelodysplastic Syndromes, Multiple Myeloma
Interventions
CD34-TK75 transduced donor lymphocytes, Sub Study - 18 FHBG PET/CT Scans
Genetic · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 4 Interventional Results available

Study of Exparel Versus Epidural for Pain Control After Thoracotomy

NCT02178553
View directory record Official record
Conditions
Pain Following Thoracotomy Surgery
Interventions
Epidural, Intercostal Bupivicaine (Exparel)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 24, 2026, 5:10 PM EDT
Completed No phase listed Observational

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

NCT04807595
View directory record Official record
Conditions
Breast Cancer
Interventions
None (Observational study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 24, 2026, 5:10 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy

NCT07175805
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Stress Urinary Incontinence, Urge Urinary Incontinence, Overactive Bladder, Pelvic Organ Prolapse, Weight Loss, Fecal Incontinence, Bariatric Surgery, glp1 Agonist
Interventions
Bariatric Surgery, GLP1 receptor agonist
Procedure · Drug
Lead sponsor
Hartford HealthCare
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 24, 2026, 5:10 PM EDT
Withdrawn No phase listed Observational

The Effect of Birth Control Methods on Anti-Mullerian Hormone (AMH) Levels

NCT01308931
View directory record Official record
Conditions
Birth Control
Interventions
Not listed
Lead sponsor
Valleywise Health
Other
Eligibility
25 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 24, 2026, 5:10 PM EDT